Literature DB >> 8243349

Some aspects of prognosis in the epilepsies: a review.

J W Sander1.   

Abstract

The traditional view that epilepsy is usually a chronic condition in which the prognosis is consistently poor has been challenged in the last 2 decades. Evidence from population-based studies and from intervention studies in newly diagnosed patients has produced a wealth of information of a much better prognosis. It is now generally accepted that as many as 70-80% of people developing seizures for the first time will eventually achieve terminal remission, whereas the remaining 20-30% will continue to have recurrent seizures despite all treatment. Despite the high recurrence rate after a first epileptic seizure, remission usually occurs early and for most persons, epilepsy is a short-lived condition. The exact role of antiepileptic drugs (AEDs) in this good outcome, however, remains open to debate, because the natural history of the untreated condition is largely unknown. In this article, factors that may influence the prognosis of the epilepsies, including the problems of diagnosis, are reviewed. Special emphasis is given to the issue of spontaneous remission and the question of prognosis of different epileptic syndromes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243349     DOI: 10.1111/j.1528-1157.1993.tb02126.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  65 in total

1.  Pros and cons for the development of new antiepileptic drugs.

Authors:  Meir Bialer; Matthew C Walker; Josemir W Sander
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 3.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

4.  Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines.

Authors:  B P Mallikarjuna; G V Suresh Kumar; B S Sastry; K P Manohara
Journal:  J Zhejiang Univ Sci B       Date:  2007-07       Impact factor: 3.066

Review 5.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 6.  Epidemiology of the epilepsies.

Authors:  J W Sander; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

7.  Eight Flurothyl-Induced Generalized Seizures Lead to the Rapid Evolution of Spontaneous Seizures in Mice: A Model of Epileptogenesis with Seizure Remission.

Authors:  Sridhar B Kadiyala; Joshua Q Yannix; Julia W Nalwalk; Dominick Papandrea; Barbara S Beyer; Bruce J Herron; Russell J Ferland
Journal:  J Neurosci       Date:  2016-07-13       Impact factor: 6.167

8.  Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome.

Authors:  Satish C Rao; Gerald Dove; Gregory D Cascino; Ronald C Petersen
Journal:  Epilepsy Behav       Date:  2008-10-08       Impact factor: 2.937

9.  Deep brain stimulation for epilepsy.

Authors:  Casey H Halpern; Uzma Samadani; Brian Litt; Jurg L Jaggi; Gordon H Baltuch
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 10.  Preventing tomorrow's sudden cardiac death in epilepsy today: what should physicians know about this?

Authors:  Fulvio A Scorza; Diego B Colugnati; Aline P Pansani; Eliza Y F Sonoda; Ricardo M Arida; Esper A Cavalheiro
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.